Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 538 participants.

Also called NCT01459809

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 538 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01459809
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Algeria, Colombia, Egypt, Guatemala, India, Iran, Lebanon, Mexico, Russia, South Africa, Tunisia, Türkiye, Ukraine, United Arab Emirates (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01459809. Randomized; no masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2014-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients
Acronym
RECOMMEND
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
GLIMEPIRIDE
Intervention (Drug)
METFORMIN
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01459809
Content hash
48c3b5c17be652da33f5c2c95bc7418792dce7c598628b51eed41e244f0d237c